472 related articles for article (PubMed ID: 17518771)
1. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
2. Genetic similarities between Spitz nevus and Spitzoid melanoma in children.
Gill M; Cohen J; Renwick N; Mones JM; Silvers DN; Celebi JT
Cancer; 2004 Dec; 101(11):2636-40. PubMed ID: 15503312
[TBL] [Abstract][Full Text] [Related]
3. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
4. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
5. Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma.
Mihic-Probst D; Perren A; Schmid S; Saremaslani P; Komminoth P; Heitz PU
Anticancer Res; 2004; 24(4):2415-8. PubMed ID: 15330192
[TBL] [Abstract][Full Text] [Related]
6. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.
van Dijk MC; Bernsen MR; Ruiter DJ
Am J Surg Pathol; 2005 Sep; 29(9):1145-51. PubMed ID: 16096402
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic BRAF and the tumor suppressor IGFBP7 in the genesis of atypical spitzoid nevomelanocytic proliferations.
Emley A; Yang S; Wajapeyee N; Green MR; Mahalingam M
J Cutan Pathol; 2010 Mar; 37(3):344-9. PubMed ID: 19788444
[TBL] [Abstract][Full Text] [Related]
8. BRAF and NRAS mutations in spitzoid melanocytic lesions.
Fullen DR; Poynter JN; Lowe L; Su LD; Elder JT; Nair RP; Johnson TM; Gruber SB
Mod Pathol; 2006 Oct; 19(10):1324-32. PubMed ID: 16799476
[TBL] [Abstract][Full Text] [Related]
9. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
10. The T1796A mutation of the BRAF gene is absent in Spitz nevi.
Palmedo G; Hantschke M; Rütten A; Mentzel T; Hügel H; Flaig MJ; Yazdi AS; Sander CA; Kutzner H
J Cutan Pathol; 2004 Mar; 31(3):266-70. PubMed ID: 14984580
[TBL] [Abstract][Full Text] [Related]
11. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
Wu J; Rosenbaum E; Begum S; Westra WH
Am J Dermatopathol; 2007 Dec; 29(6):534-7. PubMed ID: 18032947
[TBL] [Abstract][Full Text] [Related]
12. Benign nodal nevi frequently harbor the activating V600E BRAF mutation.
Taube JM; Begum S; Shi C; Eshleman JR; Westra WH
Am J Surg Pathol; 2009 Apr; 33(4):568-71. PubMed ID: 19033861
[TBL] [Abstract][Full Text] [Related]
13. Absence of BRAF and HRAS mutations in eruptive Spitz naevi.
Gantner S; Wiesner T; Cerroni L; Lurkin I; Zwarthoff EC; Landthaler M; Hafner C
Br J Dermatol; 2011 Apr; 164(4):873-7. PubMed ID: 21418173
[TBL] [Abstract][Full Text] [Related]
14. Spitz melanoma is a distinct subset of spitzoid melanoma.
Raghavan SS; Peternel S; Mully TW; North JP; Pincus LB; LeBoit PE; McCalmont TH; Bastian BC; Yeh I
Mod Pathol; 2020 Jun; 33(6):1122-1134. PubMed ID: 31900433
[TBL] [Abstract][Full Text] [Related]
15. High BRAF mutation frequency does not characterize all melanocytic tumor types.
Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
[TBL] [Abstract][Full Text] [Related]
16. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
17. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.
Knobbe CB; Reifenberger J; Reifenberger G
Acta Neuropathol; 2004 Dec; 108(6):467-70. PubMed ID: 15517309
[TBL] [Abstract][Full Text] [Related]
18. Absence of BRAF and NRAS mutations in uveal melanoma.
Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
[TBL] [Abstract][Full Text] [Related]
19. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
20. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
